TILs, Olutasidenib, T-DXd
Dec 08, 2022•18 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Tumor-Infiltrating Lymphocytes (TILs) getting closer to entering practice.
Updated survival results published from DESTINY-Breast03 (T-DXd vs. T-DM1).
A new IDH1 inhibitor, olutasidenib, is FDA-approved for relapsed or refractory AML.
For the best experience, listen in Metacast app for iOS or Android